Neurogene Inc. Proceeds from Sale and Maturity of Held-to-maturity Securities
Neurogene Inc. (NGNE) reported Proceeds from Sale and Maturity of Held-to-maturity Securities of $249.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities · last filed 2026-08-11
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2026-06-30 was $119.14M, a 75.21% increase year-over-year.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2026-03-31 was $130.00M, a 190.83% increase year-over-year.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2025-12-31 was $72.50M, a 360.32% increase year-over-year.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for the quarter ending 2025-09-30 was $99.50M, a 1037.14% increase year-over-year.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2025 was $284.70M, a 284.73% increase from fiscal 2024.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2024 was $74.00M, a 1380.00% increase from fiscal 2023.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2023 was $5.00M.
- Neurogene Inc. proceeds from sale and maturity of held-to-maturity securities for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale and Maturity of Held-to-maturity Securities 3 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 6 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 9 month | Proceeds from Sale and Maturity of Held-to-maturity Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $119.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $249.14M 10-Q · filed 2026-08-11 | $321.64M derived: sum of 3 quarters · filed 2026-08-11 | $421.14M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $130.00M 10-Q · filed 2026-05-12 | $202.50M derived: sum of 2 quarters · filed 2026-05-12 | $302.00M derived: sum of 3 quarters · filed 2026-05-12 | $370.00M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $72.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $172.00M derived: sum of 2 quarters · filed 2026-03-24 | $240.00M derived: sum of 3 quarters · filed 2026-08-11 | $284.70M 10-K · filed 2026-03-24 |
| 2025-09-30 | $99.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $167.50M derived: sum of 2 quarters · filed 2026-08-11 | $212.20M 10-Q · filed 2025-11-13 | $227.95M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $68.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $112.70M 10-Q · filed 2026-08-11 | $128.45M derived: sum of 3 quarters · filed 2026-08-11 | $137.20M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $44.70M 10-Q · filed 2026-05-12 | $60.45M derived: sum of 2 quarters · filed 2026-05-12 | $69.20M derived: sum of 3 quarters · filed 2026-05-12 | $88.70M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $15.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $24.50M derived: sum of 2 quarters · filed 2026-03-24 | $44.00M derived: sum of 3 quarters · filed 2026-03-24 | $74.00M 10-K · filed 2026-03-24 |
| 2024-09-30 | $8.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $28.25M derived: sum of 2 quarters · filed 2025-11-13 | $58.25M 10-Q · filed 2025-11-13 | $63.25M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $19.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $49.50M 10-Q · filed 2025-08-11 | $54.50M derived: sum of 3 quarters · filed 2025-08-11 | $54.50M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $30.00M 10-Q · filed 2025-05-09 | $35.00M derived: sum of 2 quarters · filed 2025-05-09 | $35.00M derived: sum of 3 quarters · filed 2025-05-09 | $35.00M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $5.00M derived: sum of 2 quarters · filed 2025-03-24 | $5.00M derived: sum of 3 quarters · filed 2025-03-24 | $5.00M 10-K · filed 2025-03-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-18 | $0.00 derived: sum of 2 quarters · filed 2024-11-18 | $0.00 10-Q · filed 2024-11-18 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $0.00 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |